Marksans Pharma Ltd
Marksans Pharma Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
Not discussed on this call: fundraise.
The short version
Management projects 15%-20% revenue growth for FY27, with some participants considering this conservative, suggesting 20%-25% could be achievable. Management is confident of 15%-20% revenue growth for FY27, with aspirations from some investors for 20%-25% growth as the new normal. - They aim to double revenue from INR3,000 crores to INR6,000 crores within the next five years. - EBITDA margins are expected in the 20%-21% range for FY27, with current margins around 25% in Q1 seen as influenced by volatility. - Profit after tax grew strongly by 173.9% YoY in Q1 FY27, reflecting operating leverage and improved margins. - Growth is expected to be broad-based across geographies, with Europe and U.S.
From Marksans Pharma Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Management projects 15%-20% revenue growth for FY27, with some participants considering this conservative, suggesting 20%-25% could be achievable.
- The company aims to double its revenue from INR3,000 crores within the next five years, indicating a strong growth trajectory.
- In the U.S., the immediate goal is to reach $300 million in revenue, with a longer-term outlook towards $400 million in about five years.
- Europe is targeted as a significant growth area with plans to expand into multiple countries through acquisitions, expecting about INR1,000 crores revenue from Europe within five years.
- Organic growth is strong, especially in UK and Europe, with 50%+ year-on-year growth reported recently in the UK market.
- Product portfolio expansion, particularly doubling product lines in existing geographies over 2-3 years, will support volume growth.
- OTC remains a key segment, particularly in the U.S., constituting roughly 70-75% of sales, while Europe leans more on prescription products.
Profitability & Margins
See what Marksans Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Marksans Pharma is exploring manufacturing capacity expansion with plans for potentially another unit in India within 1-2 years to meet 3-5 year growth goals, but no concrete plans finalized yet.
- The company is actively seeking inorganic growth opportunities and acquisitions, especially in Europe, to expand its footprint. They have done smaller deals in Europe (Netherlands, Germany) but plan more acquisitions as part of growth strategy.
- Current cash reserves (~INR1,000 crores) are expected to fuel both organic and inorganic growth, including acquisitions, but no specific large acquisition has been finalized yet.
- Management is conservative with cash usage, focusing on safe, high-return investments primarily in acquisitions rather than financial instruments.
- Strategic investment focus includes continuing to grow product portfolio and expanding into new geographies rather than e-commerce or upstream manufacturing like CRAMS.
- Working towards doubling revenue over next 5 years with strategic investments supporting this goal.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Marksans Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The order book remains strong, indicating healthy demand.
- Growth contributions are expected from multiple geographies, including the U.S., Europe, Australia, and other subsidiaries.
- The company anticipates continuing growth momentum across all markets in the current financial year.
- The focus includes scaling across geographies and accelerating new product launches.
- There is confidence in meeting the revenue target of INR4,000 crores within the next two years.
Marksans Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹856 Cr, net profit ₹149 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Marksans Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Marksans Pharma Ltd Q1 FY27 results?
Management projects 15%-20% revenue growth for FY27, with some participants considering this conservative, suggesting 20%-25% could be achievable. Management is confident of 15%-20% revenue growth for FY27, with aspirations from some investors for 20%-25% growth as the new normal. - They aim to double revenue from INR3,000 crores to INR6,000 crores within the next five years. - EBITDA margins are expected in the 20%-21% range for FY27, with current margins around 25% in Q1 seen as influenced by volatility. - Profit after tax grew strongly by 173.9% YoY in Q1 FY27, reflecting operating leverage and improved margins. - Growth is expected to be broad-based across geographies, with Europe and U.S.
What is Marksans Pharma Ltd share price analysis?
Marksans Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of 28.2 with a market cap of ₹14,560 Cr. Investors should review the full earnings analysis for detailed insights.
Is Marksans Pharma Ltd planning capital expenditure?
Marksans Pharma is exploring manufacturing capacity expansion with plans for potentially another unit in India within 1-2 years to meet 3-5 year growth goals, but no concrete plans finalized yet.
Keep Marksans Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.